

# AUTHOR QUERY SHEET

---

Author(s): Pereira, de Melo, Correia, Driusso  
Article title: Vaginal cone for postmenopausal women with stress urinary incontinence:  
randomized controlled trial  
Article no: 593211

---

Dear Author,

**Please check these proofs carefully.** It is the responsibility of the corresponding author to check against the original manuscript and approve or amend these proofs. A second proof is not normally provided. Informa Healthcare cannot be held responsible for uncorrected errors, even if introduced during the composition process. The journal reserves the right to charge for excessive author alterations, or for changes requested after the proofing stage has concluded.

The following queries have arisen during the editing of your manuscript and are marked in the margins of the proofs. Unless advised otherwise, submit all corrections using the CATS online correction form. Once you have added all your corrections, please ensure you press the “Submit All Corrections” button.

---

Page No.	Query Details	Author Reply
1	[AQ1] Affiliations are correct? Please check and advise	
3	[AQ2] We have inserted a running head. Please approve or provide an alternative.	

# Vaginal cone for postmenopausal women with stress urinary incontinence: randomized, controlled trial

V. S. Pereira, M. V. de Melo, G. N. Correia and P. Driusso

Department of Physical Therapy, Federal University of São Carlos, São Carlos, SP, Brazil

Key words: PELVIC FLOOR MUSCLE, POSTMENOPAUSAL WOMEN, URINARY INCONTINENCE, VAGINAL CONES

## ABSTRACT

**Objective** To investigate the effect of vaginal cones and pelvic floor muscle training (PFTM) in postmenopausal women with stress urinary incontinence.

**Methods** This randomized, controlled study included postmenopausal women, who complained of stress urinary incontinence. Forty-five women were allocated to three groups: a group given therapy with vaginal cones ( $n = 15$ ), a group receiving therapy with PFTM ( $n = 15$ ), and the control group ( $n = 15$ ). Subjects in the intervention groups were treated for 6 weeks with twice-weekly sessions of 40 min. Women in the vaginal cone group carried out the pelvic floor muscle strengthening with vaginal cones. The control group did not receive any treatment during the corresponding time. They were evaluated before, at the end of treatment and 6 weeks after treatment completion for primary outcomes (1-h pad test for urinary loss and pelvic floor muscle pressure) and secondary outcomes (quality of life with King's Health Questionnaire, satisfaction with treatment, and continuity of training).

**Results** For urinary leakage, there were statistical differences between the treated groups and the control group at the end of treatment and 6 weeks after treatment (all  $p < 0.01$ ; effect size: vaginal cone group  $-0.97$ ; PFMT group  $-0.96$ ). The same behavior was shown for treatment with pelvic floor muscle pressure (all  $p < 0.01$ ; effect size: vaginal cone group  $-2.58$ ; PFMT group  $-1.68$ ). There were no differences between the vaginal cone and PFMT groups in any of the evaluations. In outcomes for quality of life, significant differences were observed for incontinence impact and gravity domains when both treated groups were compared with the control group after treatment. Both groups reported similar satisfaction levels and the vaginal cone group demonstrated lower training continuity.

**Conclusion** Based on this study, there were similar positive results for treatment with the vaginal cone and pelvic floor muscle training for urinary leakage, pelvic floor muscle pressure and quality of life for postmenopausal women with stress urinary incontinence after 6 weeks.

## INTRODUCTION

Urinary incontinence (UI) is defined as any involuntary loss of urine<sup>1</sup> and shows a higher incidence among women. It is estimated that the prevalence may vary between 25 and 45% worldwide, and stress urinary incontinence (SUI) is the most common form<sup>2</sup>. This dysfunction is responsible for multiple effects on the mental and social well-being of women, affecting significantly their quality of life<sup>3</sup>. Its high incidence,

coupled with the psychological, social and economic impacts, makes UI a troubling health condition<sup>4</sup>.

It has been shown that women have a higher prevalence of UI during the menopausal period, with 70% of them relating the onset of symptoms with the cessation of menstruation<sup>5</sup>. Furthermore, the increase in life expectancy means that women spend more than one-third of their lives in the postmenopausal period<sup>6</sup> and the prevalence of UI in women in this period has been increasing, reaching to between 26.2 and

Correspondence: Dr V. S. Pereira, Universidade Federal de São Carlos, Rodovia Washington Luis, Km 235, Departamento de Fisioterapia. São Carlos, SP 13565-905, Brazil

35% of Brazilian women<sup>7</sup>. Given this situation, the need for adequate treatment to reduce the impact of UI in women in this period is clear. Currently, the International Continence Society (ICS) recommends physical therapy as the first treatment option for SUI<sup>1</sup>. Different therapies are used for physical therapy, having as their main objective the strengthening of the pelvic floor muscles<sup>8</sup>. Among them, pelvic floor muscle training using vaginal cones, as proposed by Plevnik<sup>9</sup>, seems to be effective for preventing a sense of slipping out, inducing a contraction of the pelvic floor muscles. However, the results of studies using vaginal cones are still inconclusive, since the evidence that vaginal cones are more effective than pelvic floor muscle training is limited<sup>10</sup>.

In a systematic review, Herbison and Dean<sup>10</sup> found that treatment with vaginal cones is beneficial when compared to no active treatment. However, there is no consensus on the superiority of using these devices when compared to other treatments<sup>10</sup>. Thus, the purpose of this study was to investigate the short-term effect of vaginal cones and pelvic floor muscle training in postmenopausal women with SUI. It was hypothesized that women treated with vaginal cones would demonstrate better results when compared to treatment without these devices and no treatment.

## MATERIALS AND METHODS

This was a randomized, controlled study, with parallel randomization (1 : 1 : 1), performed from April 2009 to April 2010 at the Laboratory for Assessment and Intervention on Women's Health, Federal University of São Carlos. The local

ethics committee approved the study (report #180/2008), which is in agreement with the Declaration of Helsinki. The women were recruited through newspaper and website advertisement. This study included postmenopausal women, defined by the absence of vaginal bleeding for 12 months<sup>7</sup>, with at least one episode of urine leakage during the previous month. One standard question about SUI was used to determine patient eligibility. The question is part of the King's Health Questionnaire (KHQ) scale of urinary symptoms<sup>11</sup>. This is a reliable instrument, validated in Brazilian Portuguese<sup>12</sup> and specific for women with UI. The question was 'Do you lose urine with physical activities such as coughing, sneezing, running?'. Only women who answered 'yes' to the question were recruited. Exclusion criteria also included previous treatment/surgery for UI or hormone therapy, ongoing urinary tract infections, cognitive or neurological disorder, uncontrolled hypertension, and inability to perform the proposed procedures<sup>13</sup>.

All participants signed an informed consent and were instructed about the study protocol. A total of 49 potential participants were screened and 45 met the criteria (Figure 1). They were allocated according to a computer-generated randomization list into three groups: a group given therapy with vaginal cones (VC) ( $n = 15$ ); a group receiving therapy with pelvic floor muscle training (PFTM) ( $n = 15$ ); and the control group ( $n = 15$ ). For the allocation, a researcher not involved in data collection or analysis developed a randomization schedule and produced 45 consecutively numbered, sealed, opaque envelopes containing each participant's allocation. Immediately after collecting baseline data, the evaluator opened the allocation envelope, which contained a paper on




Figure 1 Flow diagram of the study. VC, vaginal cone; PFMT, pelvic floor muscle training; CG, control group

1 which was written ‘pelvic floor muscle training’, ‘vaginal  
2 cone’ or ‘control’ group. Therefore, all participants were allo-  
3 cated to one of the three groups.

## 6 Outcome measurements

8 Only one unblinded experienced physical therapist per-  
9 formed all evaluations of the three groups. Initially, all  
10 women went through a complete physical examination and  
11 an interview regarding their thorough medical history. The  
12 VC and PFMT groups were evaluated before the treatment,  
13 at the end of treatment and 6 weeks after the treatment for  
14 primary outcomes (urinary leakage and pelvic floor muscle  
15 pressure) and secondary outcomes (quality of life, satisfac-  
16 tion with treatment, and continuity of training). The women  
17 in the control group carried out a similar evaluation just  
18 before and after the corresponding time of treatment but  
19 they were not asked about satisfaction with treatment. The  
20 primary investigator carried out a prior evaluation of the  
21 test–retest reliability. Ten women with SUI were tested on  
22 two occasions, separated by 1 week, to determine the intra-  
23 class correlation coefficients (ICC) and standard errors of  
24 measurement (SEM) for all variables.

25 The 1-h pad test was performed to evaluate urinary leakage  
26 according to the protocol proposed by Abrams and col-  
27 leagues<sup>14</sup>. The women were instructed to wear a pad which  
28 had been previously weighed on a precision balance (Denver  
29 APX200, precision of 0.0001 g, Denver Instrument, Denver,  
30 USA) and then drink 500 ml of water. After 30 min, they  
31 started performing a series of provocative exercises and, at the  
32 end of 1 h, the pad was removed, reweighed and the urinary  
33 loss calculated. The ICC and the SEM for this variable were  
34 0.99 and 0.45 g.

35 The evaluation of the pelvic floor muscle contraction  
36 pressure was carried out by the perineometer Perina Stim  
37 (Quark Medical Products, Piracicaba, Brazil), graduated from  
38 0 to 60 cmH<sub>2</sub>O and equipped with a vaginal probe. The  
39 women were positioned in the supine position, with hip and  
40 knee flexion. The vaginal probe was inserted approximately  
41 3.5 cm into the vaginal cavity and the device was calibrated.  
42 Then, the women were verbally instructed and motivated to  
43 perform three pelvic floor muscle contractions each of 3 s with  
44 maximum perceived effort. The women were also instructed  
45 to avoid using the abdominal, gluteal and hip adductor mus-  
46 cles during the contractions and carry out the ‘inward and up’  
47 movement. Only when this pelvic floor muscle movement was  
48 seen were the contractions considered valid<sup>15</sup>. The mean of  
49 three contractions was used for analysis. The ICC and SEM  
50 were 0.97 and 0.53 cmH<sub>2</sub>O, respectively.

51 For the assessment of quality of life, the KHQ was used.  
52 This questionnaire consists of 30 questions, divided into nine  
53 individually scored domains. Because it is a long question-  
54 naire, three broad domains related to UI were chosen. These  
55 domains (ICC; SEM) are: general health (0.79; 8.69), incon-  
56 tinence impact (0.82; 13.33) and gravity (0.91; 7.60). The  
57 total score ranges from 0 to 100 and a score of 100 represents

the worst possible quality of life, and 0 represents the best  
possible quality of life<sup>11</sup>.

At the end of the treatment and after a further 6 weeks,  
women in the VC and PFMT groups were questioned regard-  
ing their satisfaction with treatment. The only two response  
options available were ‘satisfied’ and ‘dissatisfied’. Answering  
‘satisfied’ indicated that the patient did not want a different  
treatment. Answering ‘dissatisfied’ indicated that the patient  
wanted a different treatment from the initial one<sup>16</sup>. In the  
follow-up evaluation (6 weeks after the treatment), the women  
were also asked if they performed the exercises at home with  
the same frequency as that of the exercises carried out during  
the supervised treatment.

## Treatment protocol

During the first session, all women were taught to contract  
the pelvic floor muscles correctly, and this was assessed by  
vaginal palpation. Moreover, a physical therapist provided  
explanations about the anatomy of the pelvic floor muscles  
and lower urinary tract, physiology, and continence  
mechanisms.

The treatment protocol was carried out under the super-  
vision of the same physical therapist that carried out the  
evaluation. Treatments for both VC and PFMT groups  
consisted of 12 individual sessions, with twice-weekly sessions  
of 40 min each. The total time of both treatments was  
6 weeks. During each session 100 contractions were per-  
formed on average, composed of phasic contractions held  
for 3 s with 6 s of rest as well as tonic contractions, held for  
5–10 s followed by 10–20 s of rest<sup>17</sup>. The pelvic floor muscle  
contraction was carried out in the supine, sitting and standing  
positions. The degree of difficulty progressed according to the  
positions adopted, the number of repetitions, and the time of  
sustained contraction. Women in the control group carried  
out no treatment during the time corresponding to the 6-week  
treatment, being re-evaluated after this time. Subsequently,  
they were referred for physiotherapy treatment.

Women in the VC group carried out the pelvic floor muscle  
strengthening with vaginal cones. For treatment, five vaginal  
cones were used (Femcone, Quark Medical Products, Piraci-  
caba, Brazil) of the same volume and size, with weight varying  
between 20 and 100 g. The cone was inserted into the vagina  
with the woman in the supine position by a trained physical  
therapist. In each session, a test was performed to determine  
the weight of the cone for proper pelvic floor muscle training.  
For the initial test, the lightest vaginal cone was introduced by  
the therapist. The patient was instructed to walk for a minute.  
If the cone was kept inside the vagina of the patient, the cone  
weight was progressively increased in order to find the maxi-  
mum weight that could be maintained inside the vaginal canal  
without it slipping out. The selected cone was used during all  
the exercises for that session. In each session, a new test was  
performed in order to increase the weight of the cone used<sup>18</sup>.

At the end of both treatments, the women were instructed  
about the importance of exercises and received a booklet

consisting of written instructions and illustrations for continuation of exercises at home twice a week. The VC group carried out the exercises at home without the vaginal cone. The control group did not receive any orientation or treatment during the corresponding treatment time. Afterwards, control group subjects were evaluated and referred for physical therapy treatment.

## Statistical analysis

All statistical analyses were performed using Statistica software (version 7.0, StatSoft Inc., Tulsa, OK, USA). All data were analyzed by intention to treat. To test the normal distribution of data in each group, the Shapiro–Wilk test was used. As the majority of data did not show normal distribution, non-parametric tests were used. The intragroup analysis in the three evaluations was carried out with the Friedman tests. Pair-wise comparisons were carried out with the Wilcoxon signed-rank test if the overall difference was statistically significant.

For the intergroup analysis before and after treatment, the Kruskal–Wallis tests were used. Pair-wise comparisons were made with the Mann–Whitney test to compare the groups. This same test was carried out for the follow-up evaluation because the analysis was composed of only two groups (VC and PFMT). Differences were considered significant when the  $p$  value was  $<0.05$ . To measure the clinical significance of the data, the effect size and the confidence interval were calculated for primary outcomes. The effect sizes were considered mild if values were smaller than 0.20, moderate if values were between 0.25 and 0.75, and large when values were over 0.80<sup>19</sup>.

## RESULTS

Forty-five participants were included at the intention-to-treat analysis (Figure 1) but two women of the PFMT group did only six and eight sessions, respectively, and discontinued treatment. There were no significant differences between the groups in terms of demographical and clinical characteristics (Table 1). The severity and type of prolapse were comparable among the groups. One woman in each treatment group and two control group patients had anterior wall prolapse grade I, according to the classification recommended by the ICS<sup>1</sup>.

There was a significant decrease in urinary leakage in the VC group when compared with the values at the end ( $p < 0.001$ ; effect size  $-0.97$ ; 95% confidence interval (CI) 0.76–6.0) and 6 weeks after treatment ( $p < 0.001$ ) and the values at baseline. The same behavior was shown for the PFMT group ( $p < 0.001$  and  $p = 0.001$ , respectively; effect size  $-0.96$ ; 95% CI 0.74–5.98). In the intergroup analysis, there was a significant difference only in the evaluation after treatment between the VC group and the control group ( $p < 0.001$ ) as well as between the PFMT group and the control group ( $p < 0.001$ ) (Table 2).

**Table 1** Demographic and clinics characteristics of the study participants ( $n = 45$ ). Data are given as mean (standard deviation)

	Vaginal cone group ( $n = 15$ )	PFMT group ( $n = 15$ )	Control group ( $n = 15$ )
Age (years)	66.33 (10.86)	63.0 (10.73)	62.92 (9.24)
Schooling (years)	9.33 (2.55)	9.98 (4.17)	10.02 (3.35)
Body mass index (kg/cm <sup>2</sup> )	27.89 (1.93)	25.65 (2.79)	26.04 (1.84)
Number of deliveries	3.06 (1.16)	2.26 (1.09)	2.81 (1.32)
Vaginal delivery	2.40 (1.41)	1.40 (1.29)	2.13 (1.46)
Menopause (years)	15.93 (9.76)	14.47 (10.10)	13.42 (9.12)
Urinary symptoms (years)	3.46 (3.04)	3.67 (3.69)	3.73 (3.36)

PFMT, pelvic floor muscle training

In the analysis of pelvic floor muscle pressure, a significant increase in pelvic floor muscle pressure was shown in the VC group ( $p < 0.001$ ; effect size 2.58; 95% CI 22.23–40.43) and in the PMFT group ( $p < 0.001$ ; effect size 1.68; 95% CI 12.86–33.76) when comparing the values at the end and 6 weeks after treatment with the values at baseline. The intergroup analysis showed statistical differences between the VC group and the control group ( $p < 0.001$ ) as well as between the PFMT group and the control group ( $p < 0.001$ ) only after treatment (Table 2). For both variables, there were no differences among treated groups in any of the evaluations. In the control group, no differences were observed between the evaluations for any variable.

A significant reduction in the scores was shown at the end and 6 weeks after treatment in the VC and PFMT groups for incontinence impact (both  $p = 0.001$ ) and gravity measures (both  $p < 0.001$ ). Similarly, in the PFMT group, a significant reduction was observed at the end and 6 weeks after treatment for incontinence impact ( $p = 0.005$  and  $p = 0.003$ ) and gravity measures. Significant differences were observed in the intergroup analysis for incontinence impact and gravity measures domains (all  $p < 0.01$ ) when both treated groups were compared with the control group after treatment (Table 3).

Regarding reported satisfaction, 14 of 15 (93.3%) of the VC group subjects and 12 of 13 (92.3%) of the PFMT group subjects showed that they were satisfied with treatment. After 6 weeks from the end of treatment, the same result was found for the two groups. In follow-up evaluation, three of 15 (20%) of the VC group subjects and one of 13 (7.7%) of the PFMT group subjects reported that they did not perform the exercises with a minimum frequency of twice per week. There were no complaints of adverse effects due to the treatment from either group.

## DISCUSSION

The benefits of strengthening pelvic floor muscles with the use of vaginal cones have been proposed by the possibility of

**Table 2** Values and intragroup and intergroup analyses of urinary leakage and pelvic floor muscle pressure for the three groups before, after treatment and 6 weeks after the end of treatment. Data are given as mean (standard deviation).

Groups	Before treatment	After treatment	6 weeks after the end of treatment	Intragroup <i>p</i> value
<i>Urinary leakage (g)</i>				
VC group	7.36 (8.76)	0.27 (0.36)*†	0.36 (0.38)*	<0.001
PFMT group	3.70 (4.35)	0.29 (0.31)*†	0.19 (0.27)*	<0.001
Control group	3.87 (5.56)	3.65 (4.94)	–	0.19
Intergroup <i>p</i> value	0.91	<0.001	0.10	
<i>Pressure (cmH<sub>2</sub>O)</i>				
VC group	12.60 (13.86)	43.24 (16.28)*†	43.29 (18.54)*	<0.001
PFMT group	12.55 (9.20)	35.22 (18.96)*†	37.38 (18.18)*	<0.001
Control group	11.42 (5.13)	11.91 (5.57)	–	0.18
Intergroup <i>p</i> value	0.76	<0.001	0.54	

\*, Differences vs. before treatment (Friedman tests); †, differences vs. Control group (Kruskal–Wallis tests)

VC, vaginal cone; PFMT, pelvic floor muscle training

providing sensory-motor biofeedback<sup>18</sup>. It is possible that this sensory-motor biofeedback could maximize the neural gains as the greatest activation and synchronization of the motor units<sup>20</sup>. Therefore, the use of vaginal cones would provide a rapid gain in muscle strength<sup>21</sup> by neural mechanisms, followed by muscle hypertrophy in response to resistance training with progression of the cone weight. Considering these possible physiological mechanisms, it has been hypothesized that the use of vaginal cones could have advantages when compared to other modalities for treatment of UI<sup>10</sup>. However, contrary to our initial hypothesis, the VC and PFMT groups demonstrated similar results for primary and secondary outcomes, indicating that muscle strengthening with and without the use of vaginal cones seem to be effective for treatment of SUI.

Similarly to the results shown in the present study, there is some evidence suggesting that vaginal cones and pelvic floor muscle training have equal benefit on the outcomes of urinary leakage, number of pads used and muscle strength<sup>18,22–24</sup>.

However, Bø and colleagues<sup>15</sup> found better results for the pelvic floor muscle training group on the outcome of urinary leakage when compared to electrical stimulation, vaginal cones, and no treatment for SUI. On the other hand, Arvonen and colleagues<sup>25</sup> showed a greater reduction in urinary leakage in the treatment group with use of vaginal cones.

The heterogeneity of populations and intervention protocols may explain the disparity of results, making it difficult to compare them<sup>10</sup>. The results of Bø and colleagues<sup>15</sup> and Arvonen and colleagues<sup>25</sup> are similar because they treated women with an average age of about 50 years and both studies measured urinary leakage through the pad test with a standardized bladder volume. However, the different protocols of these studies also may explain the differences found. Bø and colleagues<sup>15</sup> instructed the women in the PFMT group to carry out contractions three times a day, every day, and then weekly sessions of 45 min with supervision, and the women in the VC group were told to carry out the exercises for 20 min each day. Moreover, Arvonen and colleagues<sup>25</sup>

**Table 3** Values of the King's Health Questionnaire domains for the groups. Data are given as mean (standard deviation)

Groups	Before treatment	After treatment	6 weeks after the end of treatment	Intragroup <i>p</i> value
<i>General health</i>				
VC group	35.0 (20.7)	28.33 (18.6)	25.0 (13.6)	0.053
PFMT group	33.34 (18.09)	30.01 (16.90)	23.33 (6.45)	0.32
Control group	40.01 (18.4)	33.34 (18.09)	–	0.17
Intergroup <i>p</i> value	0.16	0.79	0.34	
<i>Incontinence impact</i>				
VC group	75.56 (32.0)	22.24 (20.6)*†	17.78 (17.2)*	<0.001
PFMT group	55.82 (39.32)	17.76 (24.7)*†	7.69 (14.6)*	<0.001
Control group	59.98 (33.81)	57.84 (29.48)	–	0.39
Intergroup <i>p</i> value	0.39	0.001	0.32	
<i>Gravity measures</i>				
VC group	56.47 (23.9)	17.35 (22.5)*†	8.02 (9.8)*	<0.001
PFMT group	41.33 (25.47)	15.11 (23.0)*†	5.91 (6.26)*	<0.001
Control group	46.67 (24.16)	45.80 (23.09)	–	0.21
Intergroup <i>p</i> value	0.43	0.01	0.67	

\*, Differences vs. before treatment (Wilcoxon test); †, differences vs. Control group (Mann–Whitney tests) VC, vaginal cone; PFMT, pelvic floor muscle training

1 instructed both treatment groups to conduct exercises at  
2 home and supervised sessions lasting 30 min three times a  
3 week. These authors also used vaginal balls, and not vaginal  
4 cones as in the other studies. Therefore, the format of the  
5 device may have changed the result.

6 Castro and colleagues<sup>22</sup> and Gameiro and colleagues<sup>18</sup>  
7 found similar results to the present study with the implemen-  
8 tation of protocols of 45 and 40 min, respectively, similar to  
9 the present study. However, Castro and colleagues<sup>22</sup> treated  
10 women three times per week for 6 months while patients in  
11 the study by Gameiro and colleagues<sup>18</sup> underwent treatment  
12 once weekly, for 12 weeks. Thus, the results show that treat-  
13 ment with and without the use of vaginal cones when per-  
14 formed one, two or three times a week may be effective in  
15 reducing urinary incontinence in women with SUI.

16 Although other studies have investigated the use of vaginal  
17 cones in women and found similar results, the effects of the  
18 pelvic floor muscle strengthening in the specific population of  
19 postmenopausal women have not been investigated. This  
20 population has a high incidence of lower urinary tract dys-  
21 function, possibly resulting from the sum of the effects caused  
22 by the reduction of endogenous estrogen production in the  
23 postmenopausal period and aging<sup>6</sup>. Further studies are needed  
24 to clarify the real contribution of changes due to advanced  
25 aging and the postmenopausal period, individually or together,  
26 for the greatest number of lower urinary tract dysfunctions in  
27 postmenopausal women. However, the results of the present  
28 study showed that, regardless of the structural changes in  
29 those women, vaginal cones and pelvic floor muscle training  
30 may provide benefits for SUI symptoms in women after  
31 menopause.

32 The benefits of the SUI treatment by vaginal cones and pel-  
33 vic floor muscle training remained after 6 weeks, possibly by  
34 continued exercise without supervision. Despite the VC group  
35 being treated with the vaginal cone device and it being expected  
36 to show greater motivation for treatment<sup>10</sup>, the group showed  
37 lower adherence to unsupervised exercise. This finding may  
38 be a consequence of the need to carry out the exercises with-  
39 out this device, which would reduce the motivation for the  
40 exercises.

## 44 References

- 47 1. Abrams P, Andersson KE, Birder L, *et al.* Fourth International  
48 Consultation on Incontinence Recommendations of the Interna-  
49 tional Scientific Committee: Evaluation and Treatment of Urinary  
50 Incontinence, Pelvic Organ Prolapse, and Fecal Incontinence.  
51 *Neurourol Urodyn* 2010;29:213–40
- 52 2. Buckley BS, Lapitan MCM. Prevalence of urinary incontinence  
53 in men, women, and children – current evidence: findings of the  
54 Fourth International Consultation on Incontinence. *Urology*  
55 2010;76:265–70
- 56 3. Dedicaco AC, Haddad M, Saldanha MES, Driusso P. Compara-  
57 co da qualidade de vida nos diferentes tipos de incontinncia  
urinria feminina. *Rev Bras Fisioter* 2009;13:116–22
4. Botleto R, Bell RJ, Urquhart DM, Davis SR. Urinary inconti-  
nence is associated with lower psychological general well-being in  
community-dwelling women. *Menopause* 2010;17:332–7
5. Robinson D, Cardozo LD. The role of estrogens in female lower  
urinary tract dysfunction. *Urology* 2003;62(Suppl 4A):45–51
6. Chen Y, Chen G, Hu S, Lin T, Lin L. Is the occurrence of stor-  
age and voiding dysfunction affected by menopausal transi-  
tion or associated with the normal aging process? *Menopause*  
2003;10:203–8
7. Tamanini JTN, Lebro ML, Duarte YAO, Santos JFL, Laurenti R.  
Analysis of the prevalence of and factors associated with urinary  
incontinence among elderly people in the Municipality of So

58 Treated groups showed similar improvement in the quality  
59 of life in intergroup analysis. The assessment of quality of  
60 life is recommended by the ICS as a supplement to clinical  
61 measures of UI<sup>26</sup>. However, the presence of a high standard  
62 deviation in all evaluations and all groups demonstrates the  
63 subjectivity of the assessments of quality of life<sup>3</sup>. This is  
64 because it is known that suffering and the range of difficulties  
65 are related not only to age, ethnicity and religion but also  
66 to each individual's perception of and response to the  
67 incontinence<sup>27</sup>.

68 The main limitation of our study was that the therapist that  
69 carried out the evaluation and treatment was not blinded and  
70 this could have influenced the results, consciously or not.  
71 Also, it cannot be ignored that a larger sample size could have  
72 altered some of the results of the study. When the power  
73 analysis was performed taking into account only the outcome  
74 of urinary loss for the treated groups, a low power was found  
75 (9%). Therefore, further research is required before definite  
76 conclusions can be drawn. However, despite the small sample  
77 size, the calculation of effect size showed that the treatment  
78 had a large effect on clinical variables. Future studies should  
79 also perform follow-up for periods exceeding 1 year to verify  
80 the maintenance of long-term gains.

81 In conclusion, this study verified similar positive results  
82 for treatment with vaginal cones and pelvic floor muscle  
83 training for urinary leakage, pelvic floor muscle pressure  
84 and quality of life for postmenopausal women with SUI.  
85 The group receiving pelvic floor muscle training showed  
86 greater adherence to unsupervised exercise. Thus, both treat-  
87 ments appear to be effective for treatment of stress urinary  
88 incontinence in this population. The low power may be one  
89 explanation for the lack of difference between the treated  
90 groups.

91 *Conflict of interest* The authors report no conflict of  
92 interest. The authors alone are responsible for the content  
93 and writing of the paper.

94 *Source of funding* National Council for Scientific and  
95 Technological Development (CNPq).

- 1 Paulo, Brazil: SABE Study (Health, Wellbeing and Aging). *Cad*  
2 *Saúde Pública* 2009;25:1756–62
- 3 8. Morin M, Gravel D, Bourbonnais D, Dumoulin C, Ouellet S.  
4 Reliability of dynamometric passive properties of the pelvic floor  
5 muscles in postmenopausal women with stress urinary incontine-  
6 nence. *Neurourol Urodyn* 2008;27:819–25
- 7 9. Plevnik S. New method for testing and strengthening of pelvic  
8 floor muscles. *Proceedings of the 15th Annual Meeting of the In-*  
9 *ternational Continence Society*, London, 1985:267–8
- 10 10. Herbison GP, Dean N. Weighted vaginal cones for urinary incon-  
11 tinence. *Cochrane Database Syst Rev* 2002;1:CD002114.  
12 doi:10.1002/14651858.CD002114
- 13 11. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new question-  
14 naire to assess the quality of life of urinary incontinent women.  
15 *Br J Obstet Gynaecol* 1997;104:1374–9
- 16 12. Tamanini JTN, D’Ancona CAL, Botega NJ, Netto Jr NR.  
17 Validação do King’s Health Questionnaire para o português em  
18 mulheres com incontinência urinária. *Rev Saúde Pública*  
19 2003;37:203–11
- 20 13. Neumann PB, Grimmer KA, Grant RE, Gill VA. Physiotherapy  
21 for female stress urinary incontinence: a multicentre observa-  
22 tional study. *Aust NZ J Obstet Gynaecol* 2005;45:226–32
- 23 14. Abrams P, Blaivas JG, Stanton S, Andersen JT. The standardisa-  
24 tion of terminology of lower urinary tract function. *Neurourol*  
25 *Urodyn* 1988;7:403–26
- 26 15. Bø K, Talseth T, Holme I. Single blind, randomised controlled  
27 trial of pelvic floor exercises, electrical stimulation, vaginal cones,  
28 and no treatment in management of genuine stress incontinence  
29 in women. *BMJ* 1999;318:487–93
- 30 16. Camargo FO, Rodrigues AM, Arruda RM, Sartori MGF,  
31 Girão MJ, Castro RA. Pelvic floor muscle training in female stress  
32 urinary incontinence: comparison between group training  
33 and individual treatment using PERFECT assessment scheme.  
34 *Int Urogynecol J* 2009;20:1455–62
- 35 17. Rett MT, Simoes JA, Herrmann V, Pinto CLB, Marques AA,  
36 Morais SS. Management of stress urinary incontinence with  
37 surface electromyography: assisted biofeedback in women of  
38 reproductive age. *Phys Ther* 2007;87:136–42
- 39 18. Gameiro MO, Moreira EH, Gameiro FO, Moreno JC, Padovani  
40 CR, Amaro JL. Vaginal weight cone versus assisted pelvic floor  
41 muscle training in the treatment of female urinary incontinence:  
42 a prospective, single-blind, randomized trial. *Int Urogynecol*  
43 *J* 2010;21:395–9
- 44 19. Urdan TC. *Statistics in Plain English*, 2nd edn. Mahwah, NJ:  
45 Lawrence Erlbaum Associates, 2005
- 46 20. Duchateau J, Semmler JG, Enoka RM. Training adaptations in  
47 the behavior of human motor units. *J Appl Physiol* 2006;101:  
48 1766–75
- 49 21. Wrigley T. The effect of training with vaginal weighted cones and  
50 pelvic floor exercises on the strength of the pelvic floor muscles:  
51 a pilot study. *Int Urogynecol J* 1995;6:4–9
- 52 22. Castro RA, Arruda RM, Zanetti MRD, Santos PD, Sartori MGF,  
53 Girão MJBC. Single-blind, randomized, controlled trial of pelvic  
54 floor muscle training, electrical stimulation, vaginal cones, and  
55 no active treatment in the management of stress urinary incontine-  
56 nence. *Clinics* 2008;63:465–72
- 57 23. Cammu H, Nylen M. Pelvic floor exercises versus vaginal weight  
58 cones in genuine stress incontinence. *Eur J Obstet Gynecol*  
59 *Reprod Biol* 1998;77:89–93
- 60 24. Laycock J, Brown J, Cusack C, Green S, Jerwood D, Mann K.  
61 Pelvic floor reeducation for stress incontinence: comparing three  
62 methods. *Br J Community Nurs* 2001;6:230–7
- 63 25. Arvonen T, Fianu-Jonasson A, Tyni-Lenné R. Effectiveness of two  
64 conservative modes of physical therapy in women with urinary  
65 stress incontinence. *Neurourol Urodyn* 2001;20:591–9
- 66 26. Oh SJ, Ku JH. Does condition-specific quality of life correlate  
67 with generic health-related quality of life and objective incontine-  
68 nence severity in women with stress urinary incontinence?  
69 *Neurourol Urodyn* 2006;25:324–9
- 70 27. Higa R, Lopes MHBM, Turato ER. Psychocultural meanings  
71 of urinary incontinence in women: a review. *Rev Latino-Am*  
72 *Enfermagem* 2008;16:779–86